Latest News and Press Releases

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe...

Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52...

CUMBERLAND, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...

New York, USA, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Market Overview: Polaris Market Research's latest analysis reveals that the market for idiopathic pulmonary fibrosis treatment is on a growth...

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline...

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis

Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of...

Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis ...

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...